Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD
Status:
Terminated
Trial end date:
2010-10-22
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, extension study of patients with late infantile MLD who
have previously completed clinical study HGT-MLD-048 (NCT00633139), defined as the completion
of all Week 52 procedures. This group of patients will be offered ongoing treatment with
HGT-1111 in this protocol. One infusion will be given every other week until the product is
commercially available, the patient discontinues, or the study is terminated by the Sponsor,
provided no safety issues have emerged.